Efficacy and Prognostic Analysis of 315 Stage I–IVa Esophageal Cancer Patients Treated with Simultaneous Integrated Boost-Intensity-Modulated Radiation Therapy

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• MoritaM, YoshidaR, IkedaK, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery. 2008;143(4):499–508. doi:10.1016/j.surg.2007.12.00718374047
   PubMed Web of Science ®Google Scholar
• ChiuPW, ChanAC, LeungSF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. 2005;9(6):794–802. doi:10.1016/j.gassur.2005.05.00516187480
   PubMed Web of Science ®Google Scholar
• ZhangWZ, ChenJZ, LiDR, et al. Simultaneous modulated accelerated radiation therapy for esophageal cancer: a feasibility study. World J Gastroenterol. 2014;20:13973–13980. doi:10.3748/wjg.v20.i38.1397325320535
   PubMed Web of Science ®Google Scholar
• WelshJ, PalmerMB, AjaniJA, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012;82(1):468–474. doi:10.1016/j.ijrobp.2010.10.02321123005
   PubMed Web of Science ®Google Scholar
• WelshJ, SettleSH, AminiA, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118(10):2632–2640. doi:10.1002/cncr.2658622565611
   PubMed Web of Science ®Google Scholar
• WelshJW, SeyedinSN, AllenPK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol. 2017;12(2):375–382. doi:10.1016/j.jtho.2016.10.01327794500
   PubMed Web of Science ®Google Scholar
• RistauJ, ThielM, KatayamaS, et al. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol. 2021;16(1):23. doi:10.1186/s13014-021-01749-x33522923
   PubMed Web of Science ®Google Scholar
• XuY, WangZ, LiuG, et al. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: a single institution experience. J Cancer Res Ther. 2016;12(5):82–88. doi:10.4103/0973-1482.19164027721262
   PubMed Web of Science ®Google Scholar
• LinS, WangL, MylesB, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1078–1085. doi:10.1016/j.ijrobp.2012.02.01522867894
   PubMed Web of Science ®Google Scholar
• CooperJS, GuoMD, HerskovicA, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–1627. doi:10.1001/jama.281.17.162310235156
   PubMed Web of Science ®Google Scholar
• KatoK, MuroK, MinashiK, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–690. doi:10.1016/j.ijrobp.2010.06.03320932658
   PubMed Web of Science ®Google Scholar
• LiJ, GongY, DiaoP, et al. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis. Radiat Oncol. 2018;13(1):12. doi:10.1186/s13014-018-0958-529357883
   PubMed Web of Science ®Google Scholar
• ZhaoZ, WenY, LiaoD, et al. Single-agent versus double-agent chemotherapy in concurrent chemoradiotherapy for esophageal squamous cell carcinoma: prospective, randomized, multicenter phase II clinical trial. Oncologist. 2020;25(12):e1900–e1908. doi:10.1634/theoncologist.2020-080832864805
   PubMed Web of Science ®Google Scholar
• JiangN, GeXL, ZhangZY, et al. Prognostic factors for patients with esophageal cancer receiving definitive radiotherapy alone: a retrospective analysis. Cancer Manag Res. 2021;13:3229–3234. doi:10.2147/CMAR.S30067233880065
   PubMed Web of Science ®Google Scholar
• ZhaoL, ZhouY, PanH, et al. Radiotherapy alone or concurrent chemoradiation for esophageal squamous cell carcinoma in elderly patients. J Cancer. 2017;8(16):3242–3250. doi:10.7150/jca.2083529158796
   PubMed Web of Science ®Google Scholar
• YinH, LiD, ZhuC, et al. Factors relevant to the prognosis of patients with esophageal cancer who received intensity-modulated radiotherapy. Thorac Cancer. 2018;9(10):1215–1219. doi:10.1111/1759-7714.1280030070063
   PubMed Web of Science ®Google Scholar
• DuXX, YuR, WangZF, et al. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy. Bosn J Basic Med Sci. 2019;19:186–194.30877837
   PubMed Web of Science ®Google Scholar
• HuangC, ZhuY, LiQ, et al. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: experience of two centers. Cancer Med. 2019;8(1):28–39. doi:10.1002/cam4.178830600600
   PubMed Web of Science ®Google Scholar
• YeomJG, KimJ-H, KimJW, et al. Prognostic significance of interim response evaluation during definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers. 2021;13(6):1255. doi:10.3390/cancers1306125533809157
   PubMed Web of Science ®Google Scholar
• ChenM, LiuP, ChenY, et al. Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. Cancer Manag Res. 2019;11:3361–3369. doi:10.2147/CMAR.S19852431114372
   PubMed Web of Science ®Google Scholar
• CunninghamD, AllumWH, StenningSP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa05553116822992
   PubMed Web of Science ®Google Scholar
• AndoN, IizukaT, IdeH, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592–4596. doi:10.1200/JCO.2003.12.09514673047
   PubMed Web of Science ®Google Scholar
• ZhangL, LiW, LyuX, et al. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Chin J Cancer Res. 2017;29(2):149–155. doi:10.21147/j.issn.1000-9604.2017.02.0828536494
   PubMed Web of Science ®Google Scholar
• XiaX, LiuZ, QinQ, et al. Long-term survival in nonsurgical esophageal cancer patients who received consolidation chemotherapy compared with patients who received concurrent chemoradiotherapy alone: a systematic review and meta-analysis. systematic review. Front Oncol. 2021;10:604657. doi:10.3389/fonc.2020.60465733489910
   PubMed Web of Science ®Google Scholar